4.7 Article

Clinical Characteristics and Risk Factors of Lung Injury Induced by Nab-Paclitaxel

Related references

Note: Only part of the references are listed.
Article Critical Care Medicine

Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society

Hiroto Hatabu et al.

LANCET RESPIRATORY MEDICINE (2020)

Review Chemistry, Multidisciplinary

nab-Paclitaxel mechanisms of action and delivery

Denise A. Yardley

JOURNAL OF CONTROLLED RELEASE (2013)

Article Medicine, General & Internal

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Review Respiratory System

Consensus statement for the diagnosis and treatment of drug-induced lung injuries

Keishi Kubo et al.

RESPIRATORY INVESTIGATION (2013)

Review Respiratory System

Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches

Osamu Matsuno

RESPIRATORY RESEARCH (2012)

Article Critical Care Medicine

Interstitial lung disease in Japanese patients with lung cancer - A cohort and nested case-control study

Shoji Kudoh et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)

Letter Oncology

Acute lung injury associated with docetaxel and bevacizumab

A. Prat et al.

CLINICAL ONCOLOGY (2007)

Article Cardiac & Cardiovascular Systems

Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone

Yuichiro Yamada et al.

CIRCULATION JOURNAL (2007)